Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (361-370 of 379) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5Markus Sieber, Hans Tesch, Beate Pfistner, et al.
The New England Journal of Medicine|September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphomaAndreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Haematologica|May 4, 2023
B-cell receptor reactivity against <i>Rothia mucilaginosa</i> in nodular lymphocyte-predominant Hodgkin lymphomaLorenz Thurner, Natalie Fadle, Evi Regitz, et al.
Nature Communications|October 24, 2013
Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphomaMatthew Frampton, Miguel Inacio da Silva Filho, Peter Broderick, et al.
Med (New York, N.Y.)|May 19, 2022
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detectionSophia Sobesky, Laman Mammadova, Melita Cirillo, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Blood|September 9, 2018
Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphomaAmit Sud, Hauke Thomsen, Giulia Orlando, et al.
Pageof 38

Showing results (361-370 of 379) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5Markus Sieber, Hans Tesch, Beate Pfistner, et al.
The New England Journal of Medicine|September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphomaAndreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Haematologica|May 4, 2023
B-cell receptor reactivity against <i>Rothia mucilaginosa</i> in nodular lymphocyte-predominant Hodgkin lymphomaLorenz Thurner, Natalie Fadle, Evi Regitz, et al.
Nature Communications|October 24, 2013
Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphomaMatthew Frampton, Miguel Inacio da Silva Filho, Peter Broderick, et al.
Med (New York, N.Y.)|May 19, 2022
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detectionSophia Sobesky, Laman Mammadova, Melita Cirillo, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Blood|September 9, 2018
Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphomaAmit Sud, Hauke Thomsen, Giulia Orlando, et al.
Pageof 38